Health
FDA grants accelerated approval to Nilkarmi for advanced ALK-positive lung cancer
Coverage
2 reports · over 1 hour
The US Food and Drug Administration has granted accelerated approval to Nilkarmi, a third-generation ALK inhibitor, for adults with advanced ALK-positive non-small cell lung cancer.
- The FDA said the approval, granted ahead of a November 27 target date, rests on results from the phase 1 and 2 ALKOVE-1 trial.
- It covers adults with advanced ALK-positive non-small cell lung cancer previously treated with alectinib alone or two or more ALK inhibitors plus platinum chemotherapy.
- In the ALKOVE-1 trial, 49% of 67 patients previously given alectinib responded, and 32% of 155 patients given two or more ALK inhibitors plus chemotherapy responded.
- Nilkarmi is the second Nuvalent lung cancer drug to win US approval after GSK's $10.6 billion purchase, completed in July.

